Dubai, United Arab Emirates, [21 June 2023] NewBridge Pharmaceuticals (“NewBridge” or “the Company”) announce that they have entered a distribution agreement with Biogen International GmbH (Biogen) for the distribution and commercialization of certain Biogen Multiple Sclerosis products in selected countries in the Middle East and North Africa (“MENA”).
Joe Henein, President & CEO of NewBridge Pharmaceuticals commented:
“It is a privilege for NewBridge to work with Biogen across selected markets in MENA”, commented Joe Henein, President and CEO of NewBridge. “With NewBridge presence in these markets and working in close engagement with the neurology healthcare community, we want to ensure continuity and improvement to access for these long-term and life changing therapies. We look forward to working with Biogen to assist and bring relief to the patients living with multiple sclerosis and those who need it the most. The agreement with Biogen marks an important step forward for NewBridge and testament to our relentless determination to access innovative treatment solutions to patients in this region”, he added.
Founded in 2010, and headquartered in Dubai, United Arab Emirates, NewBridge Pharmaceuticals FZ LLC (NBP) is a dedicated partner for Biopharma and operate across Middle East and Northern African Countries (MENA) offering a comprehensive platform of services and an extended physical reach across multiple geographies within the region.
A fast-growing regional specialty organization provides critical innovative and life-changing products addressing unmet medical needs through partnership with biopharma to the patients in the region. NBP has gathered outstanding talents in multiple therapeutic areas such as neuroscience, oncology-hematology, immunology, metabolic and rare diseases.